New Studies Improve Blue Light Treatment For Psoriasis

New study supports the use of virtual patients and in silico clinical studies to evaluate the effectiveness of blue light to reduce the symptoms of psoriasis. Researchers also demonstrated that this in silico approach can be used to improve the treatment response of patients with psoriasis to blue light by modifying the settings of the therapeutic protocol; as report in the study publish in Systems Medicine, an open access journal from Mary Ann Liebert, Inc., publishers.

Studies have shown that irradiating the skin of psoriasis vulgaris patients with blue light is effective in managing this chronic inflammatory skin condition. It decreases the characteristic symptoms of psoriasis, that is, hyperproliferation; also reduce differentiation of the structural skin cells known as keratinocytes, and sustained inflammation; without the detrimental side effects of the current phototherapy approaches.

Blue Light for Psoriasis

Despite the beneficial effects of blue light in psoriasis; so no clear guidelines have establish regarding the irradiation settings that yield the highest treatment efficacy. The irradiation settings that define the blue light treatment protocols for psoriasis are fluence; express in J/cm2, intensity, defined in mW/cm2, treatment length, specify in weeks, and frequency of treatment sessions. Clinical investigations have only studied the impact of specific combinations of these settings on the treatment efficacy; which measure by the change from baseline (cfb) of the local psoriasis severity index (LPSI).

“In silico Clinical Studies on the Efficacy of Blue Light for Treating Psoriasis in Virtual Patients” was coauthor by Zandra Félix Garza, Peter Hilbers, and Natal van Riel, Eindhoven University of Technology, The Netherlands, and Joerg Liebmann and Matthias Born, Philips Electronics Netherlands BV, Eindhoven. The researchers note that the current computational model; so for studying the efficacy of blue light therapy only reproduces the response in the average patient in clinical trials; also does not take into account individual variations amongst patients.

Pool of virtual patients

Use of a computational model combine with a refine pool of virtual patients; who can adequately capture the patient variability in the response to treatment with blue light and the decrease in disease severity seen in previous clinical investigations. The authors suggest that a minimum of 2,500 virtual patients; which they refine down from an initial pool of 500,000 virtual patients; are need to reproduce the responses seen in clinical investigations.

This study contributes to the systematic selection of the adequate blue light treatment protocol for a specific population of psoriasis patients. It enables the current model of blue light irradiation; so for psoriasis to reflect the inter subject variability typically observe in clinical investigations and proposes the use of in silico clinical studies in the field of dermatology; so particularly for chronic inflammatory skin diseases.